Working... Menu

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03693612
Recruitment Status : Recruiting
First Posted : October 3, 2018
Last Update Posted : February 15, 2019
MedImmune LLC
Information provided by (Responsible Party):

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : June 16, 2022
  Estimated Study Completion Date : June 16, 2022